stockportfolio.pro
Stocks / JAZZ vs SOLV
JAZZ vs SOLV
Jazz Pharmaceuticals plc and Solventum Corporation side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Jazz Pharmaceuticals plc (JAZZ) | Solventum Corporation (SOLV) | |
|---|---|---|
| Market cap | $14.4B | $14.3B |
| Revenue (latest FY) | $4.27B | $8.32B |
| Net income (latest FY) | $-356.15M | $1.56B |
| Revenue growth (5y CAGR) | 12.5% | 0.8% |
| Net margin | -8.3% | 18.7% |
| Return on equity | -8.2% | 30.8% |
| P/E ratio | 2080.5 | 10.1 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 4 |
| Positive free cash flow | Yes | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open JAZZ — free Open SOLV — freeFrequently asked questions
Which is bigger, JAZZ or SOLV?
Jazz Pharmaceuticals plc is larger by market capitalization — $14.4B versus $14.3B.
Which grows faster, JAZZ or SOLV?
Over the last five fiscal years, Jazz Pharmaceuticals plc grew revenue faster — 12.5%/yr versus 0.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.